Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 253

1.

Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease.

Pagano G, Niccolini F, Wilson H, Yousaf T, Khan NL, Martino D, Plisson C, Gunn RN, Rabiner EA, Piccini P, Foltynie T, Politis M.

Mov Disord. 2019 Jun 3. doi: 10.1002/mds.27733. [Epub ahead of print]

PMID:
31158314
2.

Image-based analysis and long-term clinical outcomes of deep brain stimulation for Tourette syndrome: a multisite study.

Johnson KA, Fletcher PT, Servello D, Bona A, Porta M, Ostrem JL, Bardinet E, Welter ML, Lozano AM, Baldermann JC, Kuhn J, Huys D, Foltynie T, Hariz M, Joyce EM, Zrinzo L, Kefalopoulou Z, Zhang JG, Meng FG, Zhang C, Ling Z, Xu X, Yu X, Smeets AY, Ackermans L, Visser-Vandewalle V, Mogilner AY, Pourfar MH, Almeida L, Gunduz A, Hu W, Foote KD, Okun MS, Butson CR.

J Neurol Neurosurg Psychiatry. 2019 May 25. pii: jnnp-2019-320379. doi: 10.1136/jnnp-2019-320379. [Epub ahead of print]

3.

Mitochondria function associated genes contribute to Parkinson's Disease risk and later age at onset.

Billingsley KJ, Barbosa IA, Bandrés-Ciga S, Quinn JP, Bubb VJ, Deshpande C, Botia JA, Reynolds RH, Zhang D, Simpson MA, Blauwendraat C, Gan-Or Z, Gibbs JR, Nalls MA, Singleton A; International Parkinson’s Disease Genomics Consortium (IPDGC), Ryten M, Koks S.

NPJ Parkinsons Dis. 2019 May 22;5:8. doi: 10.1038/s41531-019-0080-x. eCollection 2019.

4.

L-dopa responsiveness in early Parkinson's disease is associated with the rate of motor progression.

Malek N, Kanavou S, Lawton MA, Pitz V, Grosset KA, Bajaj N, Barker RA, Ben-Shlomo Y, Burn DJ, Foltynie T, Hardy J, Williams NM, Wood N, Morris HR, Grosset DG; PRoBaND clinical consortium.

Parkinsonism Relat Disord. 2019 May 14. pii: S1353-8020(19)30243-3. doi: 10.1016/j.parkreldis.2019.05.022. [Epub ahead of print]

PMID:
31105012
5.

Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson's disease heritability.

Reynolds RH, Botía J, Nalls MA; International Parkinson’s Disease Genomics Consortium (IPDGC); System Genomics of Parkinson’s Disease (SGPD), Hardy J, Gagliano Taliun SA, Ryten M.

NPJ Parkinsons Dis. 2019 Apr 17;5:6. doi: 10.1038/s41531-019-0076-6. eCollection 2019.

6.

Proximity extension assay testing reveals novel diagnostic biomarkers of atypical parkinsonian syndromes.

Jabbari E, Woodside J, Guo T, Magdalinou NK, Chelban V, Athauda D, Lees AJ, Foltynie T, Houlden H, Church A, Hu MT, Rowe JB, Zetterberg H, Morris HR.

J Neurol Neurosurg Psychiatry. 2019 Jul;90(7):768-773. doi: 10.1136/jnnp-2018-320151. Epub 2019 Mar 13.

7.

A Randomized Trial Directly Comparing Ventral Capsule and Anteromedial Subthalamic Nucleus Stimulation in Obsessive-Compulsive Disorder: Clinical and Imaging Evidence for Dissociable Effects.

Tyagi H, Apergis-Schoute AM, Akram H, Foltynie T, Limousin P, Drummond LM, Fineberg NA, Matthews K, Jahanshahi M, Robbins TW, Sahakian BJ, Zrinzo L, Hariz M, Joyce EM.

Biol Psychiatry. 2019 May 1;85(9):726-734. doi: 10.1016/j.biopsych.2019.01.017. Epub 2019 Jan 30.

8.

Beta synchrony in the cortico-basal ganglia network during regulation of force control on and off dopamine.

Fischer P, Pogosyan A, Green AL, Aziz TZ, Hyam J, Foltynie T, Limousin P, Zrinzo L, Samuel M, Ashkan K, Da Lio M, De Cecco M, Fornaser A, Brown P, Tan H.

Neurobiol Dis. 2019 Mar 6;127:253-263. doi: 10.1016/j.nbd.2019.03.004. [Epub ahead of print]

9.

The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease.

Wilson H, Pagano G, Niccolini F, Muhlert N, Mehta MA, Searle G, Gunn RN, Rabiner EA, Foltynie T, Politis M.

Parkinsonism Relat Disord. 2019 Feb 22. pii: S1353-8020(19)30073-2. doi: 10.1016/j.parkreldis.2019.02.027. [Epub ahead of print]

PMID:
30824285
10.

Glucagon-like Peptides (GLP-1) Perspectives in Synucleinopathies Treatment.

Foltynie T, Athauda D.

Mov Disord Clin Pract. 2018 Apr 15;5(3):255-258. doi: 10.1002/mdc3.12611. eCollection 2018 May-Jun. No abstract available.

11.

Chronic Subthalamic Nucleus Stimulation in Parkinson's Disease: Optimal Frequency for Gait Depends on Stimulation Site and Axial Symptoms.

Di Giulio I, Kalliolia E, Georgiev D, Peters AL, Voyce DC, Akram H, Foltynie T, Limousin P, Day BL.

Front Neurol. 2019 Feb 8;10:29. doi: 10.3389/fneur.2019.00029. eCollection 2019.

12.

Long-term outcomes of deep brain stimulation in Parkinson disease.

Limousin P, Foltynie T.

Nat Rev Neurol. 2019 Apr;15(4):234-242. doi: 10.1038/s41582-019-0145-9. Review.

PMID:
30778210
13.

The long-term outcome of impulsive compulsive behaviours in Parkinson's disease.

Barbosa PM, Djamshidian A, O'Sullivan SS, de Pablo-Fernandez E, Korlipara P, Morris HR, Bhatia KP, Limousin P, Foltynie T, Lees AJ, Warner TT.

J Neurol Neurosurg Psychiatry. 2019 Feb 1. pii: jnnp-2018-319891. doi: 10.1136/jnnp-2018-319891. [Epub ahead of print] No abstract available.

PMID:
30709896
14.

Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease: A Secondary Analysis of the Exenatide-PD Trial.

Athauda D, Gulyani S, Karnati H, Li Y, Tweedie D, Mustapic M, Chawla S, Chowdhury K, Skene SS, Greig NH, Kapogiannis D, Foltynie T.

JAMA Neurol. 2019 Jan 14. doi: 10.1001/jamaneurol.2018.4304. [Epub ahead of print] Erratum in: JAMA Neurol. 2019 Apr 1;76(4):509.

PMID:
30640362
15.

Effect of Low versus High Frequency Subthalamic Deep Brain Stimulation on Speech Intelligibility and Verbal Fluency in Parkinson's Disease: A Double-Blind Study.

Grover T, Georgiev D, Kalliola R, Mahlknecht P, Zacharia A, Candelario J, Hyam J, Zrinzo L, Hariz M, Foltynie T, Limousin P, Jahanshahi M, Tripoliti E.

J Parkinsons Dis. 2019;9(1):141-151. doi: 10.3233/JPD-181368.

PMID:
30594934
16.

Therapies to Slow, Stop, or Reverse Parkinson's Disease.

Foltynie T, Langston JW.

J Parkinsons Dis. 2018;8(s1):S115-S121. doi: 10.3233/JPD-181481.

17.

LRP10 in α-synucleinopathies.

Kia DA, Sabir MS, Ahmed S, Trinh J, Bandres-Ciga S; International Parkinson's Disease Genomics Consortium.

Lancet Neurol. 2018 Dec;17(12):1032. doi: 10.1016/S1474-4422(18)30401-0. Epub 2018 Nov 13. No abstract available.

PMID:
30507383
18.

Developing and validating Parkinson's disease subtypes and their motor and cognitive progression.

Lawton M, Ben-Shlomo Y, May MT, Baig F, Barber TR, Klein JC, Swallow DMA, Malek N, Grosset KA, Bajaj N, Barker RA, Williams N, Burn DJ, Foltynie T, Morris HR, Wood NW, Grosset DG, Hu MTM.

J Neurol Neurosurg Psychiatry. 2018 Dec;89(12):1279-1287. doi: 10.1136/jnnp-2018-318337. Epub 2018 Jul 25.

19.

Development and clinimetric assessment of a nurse-administered screening tool for movement disorders in psychosis.

Balint B, Killaspy H, Marston L, Barnes T, Latorre A, Joyce E, Clarke CS, De Micco R, Edwards MJ, Erro R, Foltynie T, Hunter RM, Nolan F, Schrag A, Freemantle N, Foreshaw Y, Green N, Bhatia KP, Martino D.

BJPsych Open. 2018 Sep 27;4(5):404-410. doi: 10.1192/bjo.2018.55. eCollection 2018 Sep.

20.

Modulation of Beta Bursts in the Subthalamic Nucleus Predicts Motor Performance.

Torrecillos F, Tinkhauser G, Fischer P, Green AL, Aziz TZ, Foltynie T, Limousin P, Zrinzo L, Ashkan K, Brown P, Tan H.

J Neurosci. 2018 Oct 10;38(41):8905-8917. doi: 10.1523/JNEUROSCI.1314-18.2018. Epub 2018 Sep 4.

Supplemental Content

Loading ...
Support Center